Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 21, 2019

Conditions
LymphomaNon-Hodgkin Lymphoma
Interventions
DRUG

PQR309

taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)

Trial Locations (1)

81377

Medizinische Klinik und Poliklinik III, Munich

Sponsors
All Listed Sponsors
collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

University Hospital Munich

OTHER

collaborator

University Hospital Freiburg

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

University of Stuttgart

OTHER

lead

PIQUR Therapeutics AG

INDUSTRY

NCT03127020 - Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients | Biotech Hunter | Biotech Hunter